LLY

985.37

+0.06%↑

JNJ

242.78

+0.49%↑

ABBV

221.98

+1.05%↑

NVS

154.41

+0.86%↑

AZN

191.58

+0.77%↑

LLY

985.37

+0.06%↑

JNJ

242.78

+0.49%↑

ABBV

221.98

+1.05%↑

NVS

154.41

+0.86%↑

AZN

191.58

+0.77%↑

LLY

985.37

+0.06%↑

JNJ

242.78

+0.49%↑

ABBV

221.98

+1.05%↑

NVS

154.41

+0.86%↑

AZN

191.58

+0.77%↑

LLY

985.37

+0.06%↑

JNJ

242.78

+0.49%↑

ABBV

221.98

+1.05%↑

NVS

154.41

+0.86%↑

AZN

191.58

+0.77%↑

LLY

985.37

+0.06%↑

JNJ

242.78

+0.49%↑

ABBV

221.98

+1.05%↑

NVS

154.41

+0.86%↑

AZN

191.58

+0.77%↑

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

27.93 1.38

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.59

Max

28.18

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.542 61.417
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+49.4% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	105M 1.7B
Ankstesnė atidarymo kaina	26.55
Ankstesnė uždarymo kaina	27.93

Naujienos nuotaikos

By Acuity

75%

25%

319 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026-03-16 00:00; UTC

Svarbiausios naujienos

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

2026-03-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026-03-15 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026-03-15 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026-03-15 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026-03-15 22:37; UTC

Rinkos pokalbiai

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026-03-15 22:18; UTC

Rinkos pokalbiai

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 03:00; UTC

Svarbiausios naujienos

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026-03-14 15:00; UTC

Svarbiausios naujienos

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026-03-14 02:03; UTC

Uždarbis

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026-03-14 01:32; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026-03-14 00:29; UTC

Įsigijimai, susijungimai, perėmimai

13D Filings -- Barrons.com

2026-03-13 22:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026-03-13 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026-03-13 22:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026-03-13 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026-03-13 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 20:02; UTC

Rinkos pokalbiai

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026-03-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026-03-13 19:35; UTC

Svarbiausios naujienos

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

49.4% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 49.4%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

319 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.